دورية أكاديمية
Respiratory manifestations of eosinophilic granulomatosis with polyangiitis (Churg-Strauss)
| العنوان: | Respiratory manifestations of eosinophilic granulomatosis with polyangiitis (Churg-Strauss) |
|---|---|
| المؤلفون: | Cottin, V., Bel, E., Bottero, P., Dalhoff, K., Humbert, M., Lazor, R., Sinico, R.A., Sivasothy, P., Wechsler, M.E., Groh, M., Marchand-Adam, Sylvain, Khouatra, C., Wallaert, B., Taillé, C., Delaval, P., Cadranel, J., Bonniaud, P., Prévôt, G., Hirschi, S., Gondouin, A., Dunogué, B., Chatté, G., Briault, A., Jayne, D., Guillevin, L., Cordier, J.-F. |
| المساهمون: | Centre de Référence des Maladies Pulmonaires Rares Hôpital Louis Pradel - HCL, Hôpital Louis Pradel CHU - HCL, Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Department of Pneumology Lyon, Hospices Civils de Lyon (HCL), Academic Medical Center - Academisch Medisch Centrum Amsterdam (AMC), University of Amsterdam Amsterdam = Universiteit van Amsterdam (UvA), Universität zu Lübeck = University of Lübeck Lübeck, Hôpital Bicêtre AP-HP, Le Kremlin-Bicêtre, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Université de Lausanne = University of Lausanne (UNIL), Cambridge University Hospitals NHS Foundation Trust, Addenbrookes Hospital, University of Colorado Anschutz Aurora, Pathologies Respiratoires : Protéolyse et Aérosolthérapie (PRPA), Université de Tours (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de Pneumologie et Immuno-Allergologie CHU LIlle, Pole Cardio-vasculaire et pulmonaire CHU Lille, Centre Hospitalier Régional Universitaire CHU Lille (CHRU Lille)-Centre Hospitalier Régional Universitaire CHU Lille (CHRU Lille), Institut de recherche en santé, environnement et travail (Irset), Université d'Angers (UA)-Université de Rennes (UR)-École des Hautes Études en Santé Publique EHESP (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), CHU Tenon AP-HP, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Theranoscan, Université Pierre et Marie Curie - Paris 6 (UPMC), Lipides - Nutrition - Cancer (U866) (LNC), Université de Bourgogne (UB)-Institut National de la Santé et de la Recherche Médicale (INSERM)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Ecole Nationale Supérieure de Biologie Appliquée à la Nutrition et à l'Alimentation de Dijon (ENSBANA), Service des maladies respiratoires CHU de Dijon, Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon, TF-2008-08, ERS |
| المصدر: | ISSN: 0903-1936. |
| بيانات النشر: | HAL CCSD European Respiratory Society |
| سنة النشر: | 2016 |
| المجموعة: | Université François-Rabelais de Tours: HAL |
| مصطلحات موضوعية: | Cohort, Term-follow-up, Consensus conference, Granulomatosis, asthma, Management, Nomenclature, Vasculitides, Antineutrophil cytoplasmic antibodies, [SDV.EE.SANT]Life Sciences [q-bio]/Ecology, environment/Health |
| الوصف: | IF 8.332 ; International audience ; The respiratory manifestations of eosinophilic granulomatosis with polyangiitis (EGPA) have not been studied in detail. In this retrospective multicentre study, EGPA was defined by asthma, eosinophilia and at least one new onset extra-bronchopulmonary organ manifestation of disease. The study population included 157 patients (mean±SD age 49.4±14.1 years), with a mean±SD blood eosinophil count of 7.4±6.4×109 L-1 at diagnosis. There was a mean±SD of 11.8±18.2 years from the onset of asthma to the diagnosis of EGPA, of 1.4±8.4 years from the first onset of peripheral eosinophilia to the diagnosis of EGPA, and of 7.4±6.4 years from EGPA diagnosis to the final visit. Despite inhaled and oral corticosteroid treatment, the severity of asthma increased 3-6 months before the onset of the systemic manifestations. Asthma was severe in 57%, 48%, and 56% of patients at diagnosis, at 3 years, and at the final visit, respectively. Persistent airflow obstruction was present in 38%, 30%, and 46% at diagnosis, at 3 years, and at the final visit, respectively. In EGPA, asthma is severe, antedates systemic manifestations by a mean of 12 years, and progresses to long-term persistent airflow obstruction despite corticosteroids in a large proportion of patients, which affects long-term management and morbidity. Copyright © 2016 ERS. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| العلاقة: | info:eu-repo/semantics/altIdentifier/pmid/27587545; hal-01406073; https://univ-rennes.hal.science/hal-01406073Test; PRODINRA: 388076; PUBMED: 27587545; WOS: 000390973800022 |
| DOI: | 10.1183/13993003.00097-2016 |
| الإتاحة: | https://doi.org/10.1183/13993003.00097-2016Test https://univ-rennes.hal.science/hal-01406073Test |
| رقم الانضمام: | edsbas.5AE005AC |
| قاعدة البيانات: | BASE |
| DOI: | 10.1183/13993003.00097-2016 |
|---|